Phuturdex › Diseases › HIV infection
Drugs in development · updated 30 October 2026
HIV infection: drugs in development
As of 30 October 2026 there are 53 active clinical trials (recruiting or ongoing, phases I–III) on 84 drugs for HIV infection. 25 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Lamuvidine | III | 1 | NCT06250504 |
| Teropavimab3BNC117-LS, GS-5423 | III | 1 | NCT07682961 |
| Zinlirvimab | III | 1 | NCT07682961 |
| VRC07-523LS | I–II | 4 | NCT06508749 |
| RHuPH20 | II | 3 | NCT05996471 |
| VH4524184 | II | 3 | NCT07202546 |
| PGDM1400LS | I–II | 2 | NCT06508749 |
| VH3810109 | II | 2 | NCT05996471 |
| VH4011499 Injection | II | 2 | NCT07816250 |
| [18F]F-AraG[18F]-AraG | II | 1 | NCT03684655 |
| Antiretrovirals | II | 1 | NCT06676410 |
| Interferon-Alpha | II | 1 | NCT00092222 |
| JL18008 | I–II | 1 | NCT07579741 |
| PGT121.414.LS | I–II | 1 | NCT06508749 |
| VRC01 | I–II | 1 | NCT02140255 |
| 3M-052-AF | I | 2 | NCT06613789 |
| [14C]VH4524184 | I | 1 | NCT07636928 |
| BG505 | I | 1 | NCT05217641 |
| CD40.HIVRI.Env | I | 1 | NCT06665646 |
| MRNA-1645-CoreG28v2 | I | 1 | NCT06694753 |
| MRNA-1645-eODGT8 | I | 1 | NCT06694753 |
| MRNA-1645-N332GT5 | I | 1 | NCT06694753 |
| SB-728mR-HSPC | I | 1 | NCT02500849 |
| VH4367310 | I | 1 | NCT07818915 |
| VH4770359 | I | 1 | NCT07525544 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CabotegravirAPRETUDE, Vocabria® | III | 9 | NCT03299049 |
| DolutegravirTivicay Pd®, Tivicay® | II–III | 8 | NCT04337450 |
| LamivudineEpivir-Hbv®, Epivir® | II–III | 5 | NCT04337450 |
| EmtricitabineEmtriva® | III | 4 | NCT05979311 |
| RilpivirineEdurant Ped®, Edurant® | III | 4 | NCT03299049 |
| FostemsavirBMS-663068, Rukobia® | III | 3 | NCT02362503 |
| LenacapavirYeztugo®, Sunlenca® | III | 2 | NCT07682961 |
| RitonavirNorvir®, Ritonavir Viatris (previously Ritonavir Mylan)® | III | 2 | NCT07792096 |
| Tenofovir alafenamideVemlidy® | III | 2 | NCT05979311 |
| AbacavirZiagen® | III | 1 | NCT07792096 |
| Bictegravir | III | 1 | NCT05979311 |
| CobicistatTybost® | II–III | 1 | NCT02016924 |
| DapagliflozinForxiga, Dapagliflozin Propanediol | III | 1 | NCT06317051 |
| DarunavirPrezista®, Darunavir Viatris (previously Darunavir Mylan)® | III | 1 | NCT07792096 |
| EzetimibeEzetemibe, Zetia® | III | 1 | NCT06317051 |
Sorted by most advanced phase and number of active trials. Showing 15 of 59 drugs.
All 84 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Acquired Immunodeficiency Syndrome 61 drugs
- Kaposi's sarcoma 15 drugs
- HIV seropositivity 4 drugs
- Smoking cessation 14 drugs
- Infection 71 drugs
- AIDS-related Kaposi sarcoma 3 drugs
- Opportunistic infection 11 drugs
- Multi-centric Castleman's Disease 15 drugs
- Metabolic syndrome 12 drugs
- Obesity 233 drugs
- Overweight 139 drugs
- Human body weight 13 drugs
Broader categories
- Urogenital Diseases 16 drugs
- Genital Diseases 7 drugs
- Communicable Diseases 12 drugs
- Infection 71 drugs
- Immune System Diseases 54 drugs
- Sexually transmitted infection 14 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Phuturdex; NLM MeSH term: D015658 “HIV Infections”.